Key regions: United Kingdom, Germany, France, South Korea, Italy
Sierra Leone, a country in West Africa, has been grappling with the COVID-19 pandemic since March 2020. The COVID-19 Vaccines market in Sierra Leone has been slowly developing, with the government and international organizations working towards vaccinating the population.
Customer preferences: The population in Sierra Leone has been hesitant to take the COVID-19 vaccine due to misinformation and mistrust of the government and international organizations. This hesitancy is not unique to Sierra Leone and is a trend seen in many developing countries. However, there has been a gradual increase in the number of people willing to take the vaccine as the government and health organizations continue to educate the public about its safety and efficacy.
Trends in the market: The COVID-19 Vaccines market in Sierra Leone has been developing at a slow pace due to the limited availability of vaccines. The government has received vaccines through the COVAX initiative and donations from other countries, but the number of doses is not sufficient to vaccinate the entire population. As a result, the government has prioritized vaccinating healthcare workers and vulnerable populations.
Local special circumstances: Sierra Leone is a developing country with limited healthcare infrastructure and resources. The government has been working with international organizations to improve the healthcare system and increase access to vaccines. However, the country still faces challenges in distributing and administering the vaccines due to limited resources and infrastructure.
Underlying macroeconomic factors: Sierra Leone's economy has been heavily impacted by the COVID-19 pandemic, with a decline in economic activity and an increase in poverty. The government has been working towards economic recovery and has received aid from international organizations to support the healthcare system and vaccine distribution. The slow development of the COVID-19 Vaccines market in Sierra Leone is a reflection of the country's limited resources and infrastructure, as well as the challenges faced by developing countries in accessing vaccines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
